US FDA seeks input on incorporating new science in regulation
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration is keen to incorporate “new science” into the regulatory decision-making process of its medical device unit and is inviting stakeholder feedback on how it should go about achieving this objective1. The agency says that new science may include novel technologies or novel uses of existing technologies, evolving information and knowledge, or new methods to support decision making.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.